Targeted oral therapy reduces disease burden and improves symptoms for patients with rare blood disorder in trial
The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis, according to results ...
Dec 11, 2023
0
28
